These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 2317558)

  • 41. Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study.
    Groeneveld DJ; Sanders YV; Adelmeijer J; Mauser-Bunschoten EP; van der Bom JG; Cnossen MH; Fijnvandraat K; Laros-van Gorkom BAP; Meijer K; Lisman T; Eikenboom J; Leebeek FWG
    Thromb Haemost; 2018 Jan; 118(1):152-160. PubMed ID: 29304535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease.
    Levene RB; Booyse FM; Chediak J; Zimmerman TS; Livingston DM; Lynch DC
    Proc Natl Acad Sci U S A; 1987 Sep; 84(18):6550-4. PubMed ID: 3306682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [von Willebrand factor and von Willebrand disease].
    Matsui T; Hamako J
    Rinsho Ketsueki; 2016; 57(10):2113-2123. PubMed ID: 27795521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease.
    de Romeuf C; Mazurier C
    Thromb Haemost; 1998 Jul; 80(1):37-41. PubMed ID: 9684782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets.
    Kroner PA; Kluessendorf ML; Scott JP; Montgomery RR
    Blood; 1992 Apr; 79(8):2048-55. PubMed ID: 1373334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.
    Ginsburg D; Konkle BA; Gill JC; Montgomery RR; Bockenstedt PL; Johnson TA; Yang AY
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3723-7. PubMed ID: 2786201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor.
    Barbon E; Kawecki C; Marmier S; Sakkal A; Collaud F; Charles S; Ronzitti G; Casari C; Christophe OD; Denis CV; Lenting PJ; Mingozzi F
    Gene Ther; 2023 Apr; 30(3-4):245-254. PubMed ID: 33456057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease.
    Schneppenheim R; Budde U; Obser T; Brassard J; Mainusch K; Ruggeri ZM; Schneppenheim S; Schwaab R; Oldenburg J
    Blood; 2001 Apr; 97(7):2059-66. PubMed ID: 11264172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).
    Mohammed S; Favaloro EJ
    Methods Mol Biol; 2017; 1646():461-472. PubMed ID: 28804848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.
    De Meyer SF; Vanhoorelbeke K; Chuah MK; Pareyn I; Gillijns V; Hebbel RP; Collen D; Deckmyn H; VandenDriessche T
    Blood; 2006 Jun; 107(12):4728-36. PubMed ID: 16478886
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gamma-interferon modulates von Willebrand factor release by cultured human endothelial cells.
    Tannenbaum SH; Gralnick HR
    Blood; 1990 Jun; 75(11):2177-84. PubMed ID: 2112031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural basis of von Willebrand factor multimerization and tubular storage.
    Zeng J; Shu Z; Liang Q; Zhang J; Wu W; Wang X; Zhou A
    Blood; 2022 Jun; 139(22):3314-3324. PubMed ID: 35148377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Endothelial von Willebrand factor regulates angiogenesis.
    Starke RD; Ferraro F; Paschalaki KE; Dryden NH; McKinnon TA; Sutton RE; Payne EM; Haskard DO; Hughes AD; Cutler DF; Laffan MA; Randi AM
    Blood; 2011 Jan; 117(3):1071-80. PubMed ID: 21048155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution.
    Berber E; James PD; Hough C; Lillicrap D
    J Thromb Haemost; 2009 Oct; 7(10):1672-9. PubMed ID: 19624459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics.
    Englender T; Lattuada A; Mannucci PM; Sadler JE; Inbal A
    Blood; 1996 Apr; 87(7):2788-94. PubMed ID: 8639896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease.
    Chen J; Hinckley JD; Haberichter S; Jacobi P; Montgomery R; Flood VH; Wong R; Interlandi G; Chung DW; López JA; Di Paola J
    Blood; 2015 Jul; 126(2):262-9. PubMed ID: 26019279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
    Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
    Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.